• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Intertek banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Pearl ready to begin Phase 3 studies of PT003

According to Pearl Therapeutics, it has completed two Phase 2b clinical studies of PT003, its inhaled combination bronchodilator for the treatment of moderate-to-severe COPD, and is “on-track to commence Phase 3 program in 2012.” One of the trials was a dose confirmation study of various doses of PT003 compared to its components, PT001 and PT005; the other was a cardiovascular safety study that demonstrated the safety of both components and the combination product.

“We were able to conduct these two studies, as well as the previously announced Phase 2b dose-ranging studies of PT001 and PT005 in approximately six months, which is a testament to both the skill and commitment of our clinical team, and the efficacy and safety profiles of our combination bronchodilator observed to date,” said Pearl CEO Chuck Bramlage. “With this operational excellence, along with the continued safety and efficacy of our bronchodilator combination, we are confident in our plan to advance PT003, PT001 and PT005 into the rigor of late-stage clinical scrutiny.”

Chief Medical Officer and Executive VP of Clinical Development Colin Reisner expressed confidence in the success of the upcoming Phase 3 program: “The totality of findings from our clinical program to date, which includes five Phase 2b studies, two Phase 1/2a studies and one Phase 1 study, present a strong foundation on which we plan to build a comprehensive Phase 3 program to support regulatory approval of PT003. I believe the world-class team of pulmonary drug development specialists that we have assembled, and our proven ability to conduct well-controlled and highly informative trials will provide the regulatory support needed to make our bronchodilator product family available for the very large patient population which suffers from the debilitating effects of COPD.”

Read the Pearl Therapeutics press release.

Share

published on January 6, 2012

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Solstice Air banner
    © 2025 OINDPnews